World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
53
Citations
12732
World Ranking
3953
National Ranking
349

Overview

Syd Johnson is affiliated with AstraZeneca in the United Kingdom. Their research primarily focuses on medicine, with a notable emphasis on immunology and microbiology.

The scientist's work encompasses several subfields, including infectious diseases, immunology, virology, epidemiology, and public health, environmental and occupational health.

Key topics addressed in their research include:

  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • Immune Cell Function and Interaction
  • Mosquito-borne diseases and control
  • Viral Infections and Vectors
  • Viral Infections and Outbreaks Research
  • Immunotherapy and Immune Responses

Johnson has contributed to research articles published in venues such as UNC Libraries and Human Immunology. Notable recent publications include:

  • "Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells," 2020, UNC Libraries
  • "Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus," 2020, UNC Libraries
  • "Uncovering new potentials: High resolution deceased donor human leukocyte antigen typing in less than 4 hours," 2024, Human Immunology

Johnson frequently collaborates with other researchers, including Julia Sung, Joy Pickeral, Liqin Liu, Sherry Stanfield-Oakley, and Chia-Ying K. Lam.

Best Publications

  • Development of a Humanized Monoclonal Antibody (MEDI-493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial Virus

    Syd Johnson;Cynthia Oliver;Gregory A. Prince;Val G. Hemming

  • Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus

    Theodore Oliphant;Michael Engle;Grant E Nybakken;Chris Doane

  • Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

    Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  • Use of a Whole Genome Approach To Identify Vaccine Molecules Affording Protection against Streptococcus pneumoniae Infection

    Theresa M. Wizemann;Jon H. Heinrichs;John E. Adamou;Alice L. Erwin

  • Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

    Herren Wu;David S. Pfarr;Syd Johnson;Yambasu A. Brewah

  • Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcγ receptors

    Jeffrey B. Stavenhagen;Sergey Gorlatov;Nadine Tuaillon;Christopher T. Rankin

  • Lethal Antibody Enhancement of Dengue Disease in Mice Is Prevented by Fc Modification

    Scott J. Balsitis;Katherine L. Williams;Ruben Lachica;Diana Flores

  • Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

    Paul A. Moore;Wenjun Zhang;G. Jonah Rainey;Steve Burke

  • In Vivo Tumor Targeting of a Recombinant Single-Chain Antigen-Binding Protein

    David Colcher;Robert Bird;Mario Roselli;Karl D. Hardman

  • Structural basis of West Nile virus neutralization by a therapeutic antibody

    Grant E. Nybakken;Theodore Oliphant;Syd Johnson;Stephen Burke

  • Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity

    Deryk Loo;Ralph F. Alderson;Francine Z. Chen;Ling Huang

  • Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis.

    John E. Adamou;Jon H. Heinrichs;Alice L. Erwin;William Walsh

  • Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytolysis and in vivo B-cell depletion.

    Syd Johnson;Stephen Burke;Ling Huang;Sergey Gorlatov

  • Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants.

    Whitney E. Purtha;Thomas F. Tedder;Syd Johnson;Deepta Bhattacharya

  • Development of a Highly Protective Combination Monoclonal Antibody Therapy against Chikungunya Virus

    Pankaj Pal;Kimberly A. Dowd;James D. Brien;Melissa A. Edeling

  • Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties

    Jeffrey L Nordstrom;Sergey Gorlatov;Wenjun Zhang;Yinhua Yang

  • Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization

    Maria-Concetta Veri;Sergey Gorlatov;Hua Li;Steve Burke

  • The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1

    Bimmi Shrestha;James D. Brien;Soila Sukupolvi-Petty;S. Kyle Austin

  • Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.

    William Hagopian;Robert J. Ferry;Nicole Sherry;David Carlin

  • Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2.

    Soila Sukupolvi-Petty;S. Kyle Austin;Michael Engle;James D. Brien

Frequent Co-Authors

Ezio Bonvini
Ezio Bonvini Center for Biologics Evaluation and Research
Scott Koenig
Scott Koenig MacroGenics (United States)
Paul A. Moore
Paul A. Moore MacroGenics (United States)
Michael S. Diamond
Michael S. Diamond Washington University in St. Louis
Daved H. Fremont
Daved H. Fremont Washington University in St. Louis
Theodore C. Pierson
Theodore C. Pierson National Institute of Allergy and Infectious Diseases
Jennifer R. Brown
Jennifer R. Brown Harvard University
Eva Harris
Eva Harris University of California, Berkeley
John D. Morrey
John D. Morrey Utah State University
Giorgio Inghirami
Giorgio Inghirami Cornell University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens doors to numerous healthcare and research careers, but many students also consider complementary pathways in nursing and mental health. For those interested in a faster entry into clinical roles, exploring accelerated nursing programs near me can be a smart move. These programs allow students with prior degrees to quickly transition into nursing careers.

If you are looking for foundational nursing credentials, the best easiest lpn programs to get into provide accessible training options. Licensed Practical Nurses often work closely with immunologists in clinical environments, supporting patient care focused on immune health.

For those aiming for advanced practice roles, considering nurse practitioner programs with easy admission can facilitate career progression without extensive barriers to entry. These programs blend clinical training with leadership skills essential in immunology-related healthcare settings.

Finally, specialized fields like psychiatric care intersect with immunology, particularly in neuroimmunology. Students can explore best online psychiatric mental health nurse practitioner programs that offer excellent clinical placements, preparing graduates for impactful roles in mental and immune health integration.

Best Scientists Citing Syd Johnson

Trending Scientists

Recently Published Articles